HC Wainwright Has Optimistic Outlook of AKRO FY2028 Earnings

Akero Therapeutics, Inc. (NASDAQ:AKRO) – Analysts at HC Wainwright lifted their FY2028 earnings estimates for Akero Therapeutics in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst E. Arce now expects that the company will earn $1.66 per share for the year, up from their previous estimate of $1.47. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Akero Therapeutics’ current full-year earnings is ($3.82) per share.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15).

Akero Therapeutics Price Performance

Shares of AKRO opened at $30.97 on Wednesday. The firm’s 50 day simple moving average is $29.27 and its 200 day simple moving average is $25.46. The company has a quick ratio of 24.89, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics has a 1-year low of $13.86 and a 1-year high of $37.00.

Hedge Funds Weigh In On Akero Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Propel Bio Management LLC grew its holdings in Akero Therapeutics by 4.9% during the 3rd quarter. Propel Bio Management LLC now owns 343,729 shares of the company’s stock valued at $9,862,000 after buying an additional 15,977 shares in the last quarter. FMR LLC grew its holdings in Akero Therapeutics by 732.1% during the 3rd quarter. FMR LLC now owns 30,337 shares of the company’s stock valued at $870,000 after buying an additional 26,691 shares in the last quarter. Summit Financial Wealth Advisors LLC purchased a new stake in Akero Therapeutics during the 3rd quarter valued at approximately $205,000. Algert Global LLC grew its holdings in Akero Therapeutics by 8.3% during the 3rd quarter. Algert Global LLC now owns 68,052 shares of the company’s stock valued at $1,952,000 after buying an additional 5,191 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Akero Therapeutics during the 3rd quarter valued at approximately $491,000.

Insiders Place Their Bets

In other news, insider Catriona Yale sold 15,485 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $32.62, for a total value of $505,120.70. Following the transaction, the insider now owns 74,158 shares in the company, valued at approximately $2,419,033.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Akero Therapeutics news, insider Catriona Yale sold 15,485 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $32.62, for a total transaction of $505,120.70. Following the completion of the transaction, the insider now owns 74,158 shares of the company’s stock, valued at approximately $2,419,033.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO William Richard White sold 75,159 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $27.21, for a total value of $2,045,076.39. Following the transaction, the chief financial officer now directly owns 41,791 shares of the company’s stock, valued at $1,137,133.11. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 428,397 shares of company stock valued at $12,997,971. 7.94% of the stock is currently owned by corporate insiders.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.